SG11202003486UA - Combination product for the treatment of cancer - Google Patents
Combination product for the treatment of cancerInfo
- Publication number
- SG11202003486UA SG11202003486UA SG11202003486UA SG11202003486UA SG11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA SG 11202003486U A SG11202003486U A SG 11202003486UA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- combination product
- combination
- product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574384P | 2017-10-19 | 2017-10-19 | |
EP18191980 | 2018-08-31 | ||
PCT/EP2018/078763 WO2019077132A1 (en) | 2017-10-19 | 2018-10-19 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003486UA true SG11202003486UA (en) | 2020-05-28 |
Family
ID=63915057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003486UA SG11202003486UA (en) | 2017-10-19 | 2018-10-19 | Combination product for the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210198365A1 (ja) |
EP (1) | EP3697816A1 (ja) |
JP (2) | JP7422070B2 (ja) |
KR (1) | KR20200072507A (ja) |
CN (1) | CN111655725A (ja) |
AU (1) | AU2018353432A1 (ja) |
BR (1) | BR112020007046A2 (ja) |
CA (1) | CA3078155A1 (ja) |
IL (1) | IL273835A (ja) |
MX (1) | MX2020004074A (ja) |
SG (1) | SG11202003486UA (ja) |
WO (1) | WO2019077132A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7504106B2 (ja) | 2019-01-17 | 2024-06-21 | デビオファーム・インターナショナル・エス・アー | がんの処置のための組合せ物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP2139490B1 (en) | 2007-04-13 | 2014-07-02 | The Regents of the University of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
TN2018000294A1 (en) * | 2016-02-24 | 2020-01-16 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Smc combination therapy for the treatment of cancer |
KR20190130644A (ko) * | 2017-03-31 | 2019-11-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
-
2018
- 2018-10-19 BR BR112020007046-7A patent/BR112020007046A2/pt unknown
- 2018-10-19 MX MX2020004074A patent/MX2020004074A/es unknown
- 2018-10-19 AU AU2018353432A patent/AU2018353432A1/en active Pending
- 2018-10-19 EP EP18789417.5A patent/EP3697816A1/en active Pending
- 2018-10-19 US US16/757,178 patent/US20210198365A1/en not_active Abandoned
- 2018-10-19 CN CN201880067991.1A patent/CN111655725A/zh active Pending
- 2018-10-19 WO PCT/EP2018/078763 patent/WO2019077132A1/en unknown
- 2018-10-19 SG SG11202003486UA patent/SG11202003486UA/en unknown
- 2018-10-19 KR KR1020207013793A patent/KR20200072507A/ko not_active Application Discontinuation
- 2018-10-19 CA CA3078155A patent/CA3078155A1/en active Pending
- 2018-10-19 JP JP2020519993A patent/JP7422070B2/ja active Active
-
2020
- 2020-04-06 IL IL273835A patent/IL273835A/en unknown
-
2023
- 2023-06-02 US US18/328,707 patent/US20240010731A1/en active Pending
-
2024
- 2024-01-15 JP JP2024003663A patent/JP2024054123A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL273835A (en) | 2020-05-31 |
US20240010731A1 (en) | 2024-01-11 |
JP7422070B2 (ja) | 2024-01-25 |
BR112020007046A2 (pt) | 2020-11-17 |
AU2018353432A1 (en) | 2020-04-23 |
KR20200072507A (ko) | 2020-06-22 |
CA3078155A1 (en) | 2019-04-25 |
CN111655725A (zh) | 2020-09-11 |
MX2020004074A (es) | 2020-10-16 |
JP2024054123A (ja) | 2024-04-16 |
EP3697816A1 (en) | 2020-08-26 |
US20210198365A1 (en) | 2021-07-01 |
JP2021500320A (ja) | 2021-01-07 |
WO2019077132A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247202A1 (zh) | 用於治療癌症的化合物 | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
HK1247129A1 (zh) | 治療癌症的聯合療法 | |
IL267795A (en) | Combined treatment for cancer | |
HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
IL259996A (en) | Combinations for cancer treatment | |
PT3576740T (pt) | Tratamento de cancro | |
IL268463A (en) | Cancer treatment | |
GB201706451D0 (en) | Cancer treatment | |
ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
IL266993A (en) | Combined therapy for cancer treatment | |
GB201707864D0 (en) | Platinum-reistant cancer treatment | |
IL274626A (en) | Cancer treatment | |
IL273835A (en) | Combined product for cancer treatment | |
PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
IL253642A0 (en) | Combined treatment for cancer | |
GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer | |
GB201713852D0 (en) | Cancer treatment | |
GB201704287D0 (en) | Treatment of cancer | |
GB201703857D0 (en) | Treatment of cancer | |
GB201702565D0 (en) | Treatment of cancer |